Patents by Inventor Kim Vilbour Andersen
Kim Vilbour Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7993898Abstract: The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 ?; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g.Type: GrantFiled: February 27, 2009Date of Patent: August 9, 2011Assignee: Novozymes A/SInventors: Kim Vilbour Andersen, Martin Schulein, Torben Henriksen, legal representative, Lars Christensen, Bo Damgaard, Claus Von der Osten
-
Publication number: 20110028378Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in any detergent in comparison to their wild type parent enzymes.Type: ApplicationFiled: October 14, 2010Publication date: February 3, 2011Applicant: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen
-
Publication number: 20110020266Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: ApplicationFiled: February 18, 2010Publication date: January 27, 2011Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Publication number: 20100330669Abstract: Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237, or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.Type: ApplicationFiled: May 5, 2010Publication date: December 30, 2010Inventors: Kim Vilbour Andersen, Mads Röpke, Jesper Mortensen Haaning, Steven Glazer
-
Publication number: 20100260741Abstract: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.Type: ApplicationFiled: February 17, 2010Publication date: October 14, 2010Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen
-
Patent number: 7807638Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.Type: GrantFiled: June 14, 2006Date of Patent: October 5, 2010Assignee: Bayer Healthcare LLCInventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7771996Abstract: Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.Type: GrantFiled: March 22, 2004Date of Patent: August 10, 2010Assignee: Bayer Healthcare LLCInventors: Kim Vilbour Andersen, Mads Röpke, Jesper Mortensen Haaning, Steven Glazer
-
Patent number: 7754682Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: October 30, 2007Date of Patent: July 13, 2010Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7700733Abstract: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.Type: GrantFiled: April 29, 2003Date of Patent: April 20, 2010Assignee: Bayer HealthCare LLCInventors: Jesper Mortensen Haaning, Kim Vilbour Andersen
-
Patent number: 7696153Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: April 13, 2010Assignee: Maxygen, Inc.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7598056Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: April 18, 2006Date of Patent: October 6, 2009Assignee: Bayer Health Care LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claes Bornaes
-
Publication number: 20090170747Abstract: The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 ?; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g.Type: ApplicationFiled: February 27, 2009Publication date: July 2, 2009Applicant: Novozymes A/SInventors: Kim Vilbour Andersen, Martin Schulein, Torben Henriksen, Lars Christensen, Bo Damgaard, Claus Von der Osten
-
Patent number: 7550565Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: June 23, 2009Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7550566Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: August 10, 2006Date of Patent: June 23, 2009Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Patent number: 7524931Abstract: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.Type: GrantFiled: June 23, 2003Date of Patent: April 28, 2009Assignee: Maxygen Holdings Ltd.Inventors: Bart Van Den Hazel, Anne Dam Jensen, Frank Bechnygaard, Kim Vilbour Andersen
-
Publication number: 20090099056Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in any detergent in comparison to their wild type parent enzymes.Type: ApplicationFiled: September 26, 2007Publication date: April 16, 2009Applicant: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen
-
Patent number: 7517974Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: March 30, 2006Date of Patent: April 14, 2009Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090088559Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.Type: ApplicationFiled: January 30, 2008Publication date: April 2, 2009Inventors: Torben Halkier, Anders Hjelholt Pedersen, Jens Sigurd Okkels, Kim Vilbour Andersen
-
Patent number: 7511024Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: April 12, 2006Date of Patent: March 31, 2009Assignee: Bayer HealthCare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7504237Abstract: A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.Type: GrantFiled: March 16, 2006Date of Patent: March 17, 2009Assignee: Maxygen Holdings Ltd.Inventors: Anne Dam Jensen, Kim Vilbour Andersen, Christian Karsten Hansen